| Literature DB >> 30717908 |
Ashish V Chintakuntlawar1, Robert L Foote2, Jan L Kasperbauer3, Keith C Bible4.
Abstract
Anaplastic thyroid cancer (ATC) is a devastating and usually incurable diagnosis. Clinical and pathologic diagnosis is best assessed at a tertiary center with concentrated ATC expertise. Expeditious multidisciplinary management is recommended for optimal patient outcomes. Based on multiinstitutional and population-based studies, multimodal therapy that includes chemoradiotherapy with surgery (when feasible) is the preferred initial treatment because it is associated with incrementally improved overall survival. In ATC that carries a BRAF V600E somatic mutation, combination therapy with BRAF and MEK inhibitors has shown promise but needs further study. Immunotherapeutic agents in neoadjuvant and metastatic settings are being investigated.Entities:
Keywords: Anaplastic thyroid cancer; Chemoradiotherapy; Multimodality therapy; Systemic therapy
Mesh:
Year: 2019 PMID: 30717908 DOI: 10.1016/j.ecl.2018.10.010
Source DB: PubMed Journal: Endocrinol Metab Clin North Am ISSN: 0889-8529 Impact factor: 4.741